Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9UQM7

UPID:
KCC2A_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9UQM7; Q9UL21; Q9Y2H4; Q9Y352

BACKGROUND:
The protein Calcium/calmodulin-dependent protein kinase type II subunit alpha is crucial for synaptic transmission, influencing both excitatory synaptic transmission and dendritic spine morphology. It modulates key signaling pathways, including the phosphorylation of transcription factors and the JAK-STAT pathway, in response to external stimuli.

THERAPEUTIC SIGNIFICANCE:
Given its association with Intellectual developmental disorders, exploring the functions of Calcium/calmodulin-dependent protein kinase type II subunit alpha could lead to breakthrough therapies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.